Clarity signs a large-scale Manufacturing Supply Agreement
Filed with ASX · · 2 pages · English
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal
- Co-PSMA data presented
- Registrational Phase III AMPLIFY trial: Target number of participants achieved
- AMPLIFY trial - Target number of participants achieved
- Half Yearly Report and Accounts
Later from Clarity Pharmaceuticals
- Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics
- Co-PSMA data published in the European Urology journal
- Clarity signs a Commercial Manufacturing Agreement
- Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
- Clarity receives $9.8 million R&D tax incentive refund
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals